case_images: PMC7225290_01
case_images: Representative histopathologic images of the ulcerated primary pigmented mucosal melanoma of the Urethra. (A) Overview image of the histopathologic sample, H&E stained in 2,5-fold magnification. (B) Detailed view, H&E stained in 10-fold magnification.
case_images: fonc-10-00611-g0001.jpg
case_images: PMC7225290_01_fonc-10-00611-g0001.jpg
case_images: F1
case_images: Only 1 month after the intervention intravaginal mucosal metastases were diagnosed and histologically confirmed (Figure 1).
case_images: Clinical and MR image of intravaginal mucosal metastasis of a malignant melanoma of the urethra. A/B: Visual appraisal with speculum. (A) Target lesion before injection of T-VEC. Baseline image shows a pigmented ulcerated mucosal tumor (arrow). (B) Target lesion after seven injections of T-VEC: partial response with substantial regression of the injected mucosal metastasis (arrow) and cessation of intravaginal bleeding. C/D MR image. (C) Transverse T2-weighted fat suppressed MR image shows labial metastasis (arrow) before injection of T-VEC. (D) Transverse T2-weighted fat suppressed MR image 2 months upon T-VEC therapy shows complete disappearance of labial metastasis (arrow indicating the original location).
case_images: fonc-10-00611-g0002.jpg
case_images: PMC7225290_01_fonc-10-00611-g0002.jpg
case_images: F2
case_images: Imaging confirmed loco-regional progress without distant metastases (Figure 2). After five injections T-VEC yielded a partial response with substantial regression of the injected mucosal metastases and cessation of intravaginal bleedings (Figure 2).
case_images: Summary of the sequential treatment in our case of advanced mucosal melanoma.
case_images: fonc-10-00611-g0003.jpg
case_images: PMC7225290_01_fonc-10-00611-g0003.jpg
case_images: F3
case_images: Treatment with imatinib achieved a considerable regression of all metastatic tumor sites with a still ongoing response (summary of the sequential therapies: see Figure 3).